An FDA advisory committee concluded that Coartem, a malaria treatment from Novartis AG, is safe and works against infections caused by the parasite P. falciparum. The drug, which is administered twice a day for three days, would be the first artemisinin-based combination therapy for malaria in the U.S. should it win FDA approval.

Related Summaries